Mutant superoxide dismutase 1-catalyzed hydrogen therapy for amyotrophic lateral sclerosis achieved by intercepting oxidative stress-neuroinflammation crosstalk.
Yihui Sun, Yingshuai Wang, Qianbo He, Min Zhao, Jiaru Guo, Chunjie Xu, Qiupeng Yan, Yanchun Chen, Bingqiang Zhang, Hongmei Du, Jing Huo, Yong Zhang, Haoyun Zhang, Yingjun Guan, Qianjun He · Acta biomaterialia · 2026
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In mice, although hydrogen gas (H₂) exhibits promising neuroprotective potential, conventional H₂ therapy is severely limited by unstable and transient H₂ release, failing to sustain long-term treatment requirements for chronic ALS pathogenesis. These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.
What the Findings Mean
H2HUBB reviewed how molecular hydrogen affected the outcomes measured in mice. Although hydrogen gas (H₂) exhibits promising neuroprotective potential, conventional H₂ therapy is severely limited by unstable and transient H₂ release, failing to sustain long-term treatment requirements for chronic ALS pathogenesis.
What the Researchers Studied
The researchers studied mice. The study used a preclinical animal experiment.
What Effects Did Molecular Hydrogen Have?
Here, the researchers uncover that mutant SOD1 is both a Fenton-like agent able for catalytical generation of ·OH and a hydrogenation catalyst for H₂ scavenging reactive oxygen species. Although hydrogen gas (H₂) exhibits promising neuroprotective potential, conventional H₂ therapy is severely limited by unstable and transient H₂ release, failing to sustain long-term treatment requirements for chronic ALS pathogenesis.
Why These Findings Matter
These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.
How Strong Is This Evidence?
This is preclinical animal evidence from a preclinical animal experiment. It is most informative for the disease model, mechanisms, biomarkers, and outcomes directly measured in the study.
Technical Study Details
H2HUBB classifies this publication as animal study with preclinical animal evidence. The research population or model was mice. The study used a preclinical animal experiment.
Limitations and Safety
Reported limitations: Although hydrogen gas (H₂) exhibits promising neuroprotective potential, conventional H₂ therapy is severely limited by unstable and transient H₂ release, failing to sustain long-term treatment requirements for chronic ALS pathogenesis.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.